AOD-9604: Clinical Guide for Prescribing Practices

AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) that has been studied for its effects on fat metabolism and body composition. Unlike full growth hormone, it does not affect blood sugar or growth, making it a targeted option for body composition programs.

Growth Hormone Support Popularity: Medium

Also Known As

Anti-Obesity Drug 9604 Advanced Obesity Drug

How AOD-9604 Works

AOD-9604 is a synthetic analog of the lipolytic fragment of human growth hormone (hGH 177-191) with an added tyrosine residue [1]. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) by mimicking the fat-metabolizing action of natural growth hormone without activating the IGF-1 pathway [2]. This selectivity means it does not affect blood glucose, insulin sensitivity, or promote cellular proliferation.

Clinical Evidence

Preclinical studies by Heffernan et al. demonstrated that the hGH fragment 177-191 stimulates lipolysis in adipose tissue and inhibits lipogenesis both in vitro and in vivo [1]. Stier et al. confirmed lipolytic activity in human adipose tissue explants, showing dose-dependent fat mobilization without IGF-1 elevation [2]. The compound received FDA GRAS status for use in food products in 2007, supporting its safety profile [3]. Early clinical trials in Australia showed modest weight loss versus placebo over 12 weeks, though the original pharmaceutical development program was discontinued [4].

Clinical Uses

Fat metabolism and body composition optimization
Weight management support (as adjunct to lifestyle changes)
Metabolic health improvement

Patient Selection and Screening

Best suited for patients seeking modest body composition improvement who cannot tolerate GLP-1 agonists, prefer a non-appetite-suppressant approach, or want an adjunct to GLP-1 therapy targeting fat metabolism directly. Good candidates include those with localized adiposity, patients wanting to avoid GI side effects of incretin therapies, or those with contraindications to GLP-1 agonists. Not appropriate as monotherapy for clinically significant obesity; position within full metabolic programs [2].

Dosing and Administration

Standard subcutaneous dosing is 300mcg daily, administered in the morning on an empty stomach (fasting for at least 2 hours before and 1 hour after injection) [2]. Treatment courses typically run 12-24 weeks. Some protocols use 250-500mcg daily depending on patient response and clinical goals. Can be combined with other peptides (CJC-1295/Ipamorelin) in body composition stacks. Dosing should be individualized based on clinical response and body composition measurements.

Route: Subcutaneous injection

Protocol notes: Typically administered via subcutaneous injection. Often used in combination with diet and exercise programs.

Side Effects and Monitoring

Injection site reactions (mild redness, transient discomfort)
Headache (uncommon, typically mild)
Mild fluid retention (rare)
No significant effects on blood glucose, IGF-1, or growth parameters reported
Generally well-tolerated with favorable safety profile in published data

Clinical Considerations

Does not affect IGF-1, blood sugar, or linear growth
Most evidence from early-phase clinical trials and preclinical data
Position within broader weight management program, not as standalone treatment
Verify current FDA compounding eligibility

Practice Economics

AOD-9604 programs typically generate $150-350 per month at retail, with wholesale cost from compounding pharmacies ranging from $30-70 per vial. While margins are moderate, it serves as an accessible entry point for patients not ready for GLP-1 therapy or as a combination add-on, increasing per-patient revenue within existing weight management programs [3].

FDA Category Status

Expected to return to Category 1 per February 2026 HHS announcement

FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.

Pharmacy Integrations

Prescribe AOD-9604 through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.

Empower Pharmacy

Empower Pharmacy

503A & 503B Compounding Pharmacy

 Strive Pharmacy

Strive Pharmacy

Compounding Pharmacy

 Olympia Pharmacy

Olympia Pharmacy

503A & 503B Compounding Pharmacy

Frequently Asked Questions

How does AOD-9604 compare to GLP-1 medications for weight loss?
They work through entirely different mechanisms. GLP-1 receptor agonists (semaglutide, tirzepatide) affect appetite and gastric emptying. AOD-9604 targets fat metabolism through a growth hormone fragment pathway. They are not interchangeable and serve different roles in weight management programs. Some practices offer both as options depending on patient needs.
Can AOD-9604 be combined with other peptides?
Yes. AOD-9604 is sometimes combined with CJC-1295/Ipamorelin or other peptides in body composition protocols. Combination therapy should be determined by the prescribing physician based on the patient's clinical profile and treatment goals.

References

  1. Heffernan et al. - The Effects of hGH Fragment on Lipid Metabolism (Endocrinology 2001)
  2. Stier et al. - AOD9604 Lipolytic Activity in Adipose Tissue (Journal of Endocrinology 2004)
  3. FDA GRAS Notice for AOD-9604 (GRN 000235)
  4. Australian TGA - AOD-9604 Evaluation History

Related Peptides in Growth Hormone Support

CJC-1295/Ipamorelin

Growth Hormone Support

View Guide →

Tesamorelin

Growth Hormone Support

View Guide →

Sermorelin

Growth Hormone Support

View Guide →

Ipamorelin

Growth Hormone Support

View Guide →

MK-677

Growth Hormone Support

View Guide →

GHRP-2

Growth Hormone Support

View Guide →

GHRP-6

Growth Hormone Support

View Guide →

Hexarelin

Growth Hormone Support

View Guide →

Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.

Prescribe AOD-9604 Through Karpa

Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.

Prescribe AOD-9604 Through Karpa